

Kim Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1334161/publications.pdf>

Version: 2024-02-01

172
papers

6,156
citations

87888

38
h-index

82547

72
g-index

174
all docs

174
docs citations

174
times ranked

5070
citing authors

#	ARTICLE	IF	CITATIONS
1	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 2014, 134, 818-823.	2.9	594
2	Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. BMJ: British Medical Journal, 2002, 325, 752-752.	2.3	334
3	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 2014, 134, 800-807.	2.9	257
4	Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation. Journal of Allergy and Clinical Immunology, 2013, 132, 1337-1347.	2.9	235
5	Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ, The, 2015, 350, h2958-h2958.	6.0	192
6	The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology. Journal of Investigative Dermatology, 2015, 135, 24-30.	0.7	184
7	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet, The, 2020, 395, 962-972.	13.7	178
8	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
9	A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. Journal of the American Academy of Dermatology, 2016, 74, 288-294.	1.2	162
10	Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine, 2013, 368, 1695-1703.	27.0	149
11	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 2017, 176, 979-984.	1.5	141
12	Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ: British Medical Journal, 2002, 324, 768-768.	2.3	135
13	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
14	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
15	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology, 2014, 171, 1318-1325.	1.5	95
16	The Eczema Priority Setting Partnership: a collaboration between patients, carers, clinicians and researchers to identify and prioritize important research questions for the treatment of eczema. British Journal of Dermatology, 2013, 168, 577-582.	1.5	91
17	A Randomised Controlled Trial of Ion-Exchange Water Softeners for the Treatment of Eczema in Children. PLoS Medicine, 2011, 8, e1000395.	8.4	88
18	Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. British Journal of Dermatology, 2013, 169, 337-343.	1.5	81

#	ARTICLE	IF	CITATIONS
19	Developing core outcome set for vitiligo clinical trials: international eâ€Delphi consensus. Pigment Cell and Melanoma Research, 2015, 28, 363-369.	3.3	81
20	The epidemiology of childhood psoriasis: a scoping review. British Journal of Dermatology, 2016, 174, 1242-1257.	1.5	77
21	What Is Meant by a â€Flareâ€in Atopic Dermatitis?. Archives of Dermatology, 2006, 142, 1190-6.	1.4	72
22	Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. British Journal of Dermatology, 2012, 167, 804-814.	1.5	72
23	A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time?. British Journal of Dermatology, 2002, 147, 513-517.	1.5	71
24	Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial. BMJ: British Medical Journal, 2011, 342, d3271-d3271.	2.3	68
25	Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. British Journal of Dermatology, 2011, 164, no-no.	1.5	66
26	Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Networkâ€™s PATCH II trial. British Journal of Dermatology, 2012, 166, 169-178.	1.5	65
27	Incidence, prevalence and mortality of bullous pemphigoid in England 1998â€“2017: a populationâ€based cohort study*. British Journal of Dermatology, 2021, 184, 68-77.	1.5	59
28	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials, 2017, 18, 343.	1.6	56
29	Prospective Registration and Outcome-Reporting Bias in Randomized Controlled Trials of Eczema Treatments: A Systematic Review. Journal of Investigative Dermatology, 2012, 132, 2727-2734.	0.7	54
30	Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. Journal of the American Academy of Dermatology, 2016, 75, 940-949.	1.2	53
31	Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (<sc>RECAP</sc>). British Journal of Dermatology, 2020, 183, 524-536.	1.5	52
32	Recommended core outcome instruments for healthâ€related quality of life, longâ€term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 2021, 185, 139-146.	1.5	52
33	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	2.9	51
34	Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ: British Medical Journal, 2018, 361, k1332.	2.3	50
35	Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305.	1.2	46
36	Cost effectiveness of a two-year home exercise program for the treatment of knee pain. Arthritis and Rheumatism, 2005, 53, 388-394.	6.7	45

#	ARTICLE	IF	CITATIONS
37	What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. <i>Acta Dermato-Venereologica</i> , 2017, 97, 86-90.	1.3	45
38	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). <i>British Journal of Dermatology</i> , 2016, 174, 287-295.	1.5	41
39	Silk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial). <i>PLoS Medicine</i> , 2017, 14, e1002280.	8.4	41
40	Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies*. <i>British Journal of Dermatology</i> , 2021, 184, 627-637.	1.5	39
41	UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> 51.	1.6	38
42	What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 910-927.	1.5	38
43	A multicentre randomised controlled trial and economic evaluation of ion-exchange water softeners for the treatment of eczema in children: the Softened Water Eczema Trial (SWET). <i>Health Technology Assessment</i> , 2011, 15, v-vi, 1-156.	2.8	38
44	Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. <i>Health Technology Assessment</i> , 2006, 10, iii, ix-87.	2.8	37
45	EVERT: cryotherapy versus salicylic acid for the treatment of verrucae â€“ a randomised controlled trial.. <i>Health Technology Assessment</i> , 2011, 15, 1-170.	2.8	36
46	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1038-1044.	1.2	35
47	Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. <i>British Journal of Dermatology</i> , 2016, 174, 386-394.	1.5	34
48	Scoping systematic review of treatments for eczema. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-480.	1.0	34
49	Feasibility, double-blind, randomised, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trial: Home Intervention of Light) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> 10	1.0	34
50	How are eczema â€“flaresâ€™ defined? A systematic review and recommendation for future studies. <i>British Journal of Dermatology</i> , 2014, 170, 548-556.	1.5	32
51	Safety of topical corticosteroids in atopic eczema: an umbrella review. <i>BMJ Open</i> , 2021, 11, e046476.	1.9	32
52	Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials. <i>PLoS ONE</i> , 2014, 9, e82694.	2.5	30
53	â€“When it goes back to my normal I supposeâ€™: a qualitative study using online focus groups to explore perceptions of â€“controlâ€™ among people with eczema and parents of children with eczema in the UK. <i>BMJ Open</i> , 2017, 7, e017731.	1.9	30
54	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1181-1186.	1.2	29

#	ARTICLE	IF	CITATIONS
55	What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors. Clinical and Experimental Dermatology, 2019, 44, 370-375.	1.3	28
56	Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership. British Journal of Dermatology, 2017, 177, 541-543.	1.5	27
57	What's new in atopic eczema? An analysis of systematic reviews published in 2010-11. Clinical and Experimental Dermatology, 2013, 38, 449-456.	1.3	26
58	How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods. British Journal of Dermatology, 2018, 178, 1135-1142.	1.5	26
59	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. British Journal of Dermatology, 2018, 179, 540-541.	1.5	25
60	A systematic review showing the lack of diagnostic criteria and tools developed for lowerâ€limb cellulitis. British Journal of Dermatology, 2019, 181, 1156-1165.	1.5	25
61	Randomized controlled trial of topical corticosteroid and homeâ€based narrowband ultraviolet B for active and limited vitiligo: results of the HIâ€Light Vitiligo Trial*. British Journal of Dermatology, 2021, 184, 828-839.	1.5	25
62	Validation of Treatment Escalation as a Definition of Atopic Eczema Flares. PLoS ONE, 2015, 10, e0124770.	2.5	24
63	What's new in atopic eczema? An analysis of systematic reviews published in 2012 and 2013. Part 1. Epidemiology, mechanisms of disease and methodological issues. Clinical and Experimental Dermatology, 2015, 40, 238-242.	1.3	24
64	Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technology Assessment, 2017, 21, 1-260.	2.8	24
65	Outcome measures for vulval skin conditions: a systematic review of randomized controlled trials. British Journal of Dermatology, 2013, 169, 494-501.	1.5	23
66	Future research priorities for lichen sclerosis â€ results of a James Lind Alliance Priority Setting Partnership. British Journal of Dermatology, 2019, 180, 1236-1237.	1.5	23
67	Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo. BMC Dermatology, 2014, 14, 10.	2.1	22
68	What's new in atopic eczema? An analysis of systematic reviews published in 2015. Part 1: epidemiology and methodology. Clinical and Experimental Dermatology, 2018, 43, 375-379.	1.3	22
69	Are accelerometers a useful tool for measuring disease activity in children with eczema? Validity, responsiveness to change, and acceptability of use in a clinical trial setting. British Journal of Dermatology, 2012, 167, 1131-1137.	1.5	21
70	The red leg dilemma: a scoping review of the challenges of diagnosing lowerâ€limb cellulitis. British Journal of Dermatology, 2019, 180, 993-1000.	1.5	21
71	Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. The Lancet Child and Adolescent Health, 2022, 6, 522-532.	5.6	20
72	To freeze or not to freeze: a cost-effectiveness analysis of wart treatment. British Journal of Dermatology, 2007, 156, 687-692.	1.5	19

#	ARTICLE	IF	CITATIONS
73	A case report and critical appraisal of the literature on the use of DermaSilk [®] in children with atopic dermatitis. Clinical and Experimental Dermatology, 2009, 34, e901-e903.	1.3	19
74	What's new in atopic eczema? An analysis of systematic reviews published in 2012 and 2013. Part 2. Treatment and prevention. Clinical and Experimental Dermatology, 2015, 40, 349-355.	1.3	19
75	Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. British Journal of Dermatology, 2017, 177, 1527-1536.	1.5	19
76	Should eye protection be worn during dermatological surgery: prospective observational study. British Journal of Dermatology, 2007, 156, 1258-1262.	1.5	18
77	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Health Technology Assessment, 2020, 24, 1-128.	2.8	18
78	Strategies for using topical corticosteroids in children and adults with eczema. The Cochrane Library, 2022, 2022, CD013356.	2.8	18
79	Cost-effectiveness of cryotherapy versus salicylic acid for the treatment of plantar warts: economic evaluation alongside a randomised controlled trial (EVerT trial). Journal of Foot and Ankle Research, 2012, 5, 4.	1.9	17
80	Incidence and sociodemographic characteristics of eczema diagnosis in children: A cohort study. Journal of Allergy and Clinical Immunology, 2018, 141, 1927-1929.e8.	2.9	17
81	Mapping Systematic Reviews on Atopic Eczema—An Essential Resource for Dermatology Professionals and Researchers. PLoS ONE, 2013, 8, e58484.	2.5	16
82	Defining and measuring “eczema control”: an international qualitative study to explore the views of those living with and treating atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1124-1132.	2.4	16
83	A multicentre randomized controlled trial of ion-exchange water softeners for the treatment of eczema in children: protocol for the Softened Water Eczema Trial (SWET) (ISRCTN: 71423189). British Journal of Dermatology, 2008, 159, ???-???.	1.5	15
84	Systemic therapy for vulval Erosive Lichen Planus (the “HELP” trial): study protocol for a randomised controlled trial. Trials, 2016, 17, 2.	1.6	15
85	Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. British Journal of Dermatology, 2018, 178, 1028-1034.	1.5	15
86	A systematic review of diagnostic criteria for psoriasis in adults and children: evidence from studies with a primary aim to develop or validate diagnostic criteria. British Journal of Dermatology, 2018, 178, 1035-1043.	1.5	15
87	Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT. Health Technology Assessment, 2018, 22, 1-116.	2.8	14
88	Best emollients for eczema (BEE) – comparing four types of emollients in children with eczema: protocol for randomised trial and nested qualitative study. BMJ Open, 2019, 9, e033387.	1.9	13
89	Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. British Journal of Dermatology, 2020, 183, 566-568.	1.5	13
90	Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review*. British Journal of Dermatology, 2021, 185, 921-934.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Management of cellulitis: current practice and research questions. British Journal of General Practice, 2018, 68, 595-596.	1.4	12
92	What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention. Clinical and Experimental Dermatology, 2019, 44, 363-369.	1.3	12
93	Patients' understanding of cellulitis and views about how best to prevent recurrent episodes: mixed methods study in primary and secondary care. British Journal of Dermatology, 2019, 180, 810-820.	1.5	12
94	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Research and Therapy, 2020, 22, 56.	3.5	12
95	Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care) Tj ETQq1 1 0.784314 rgBT /Over	1.9	12
96	Views and experiences of seeking information and help for vitiligo: a qualitative study of written accounts. BMJ Open, 2018, 8, e018652.	1.9	11
97	The UK clinical research network - has it been a success for dermatology clinical trials?. Trials, 2011, 12, 153.	1.6	10
98	Bath additives for the treatment of childhood eczema (BATHE): protocol for multicentre parallel group randomised trial. BMJ Open, 2015, 5, e009575.	1.9	10
99	A multi-centre, parallel group superiority trial of silk therapeutic clothing compared to standard care for the management of eczema in children (CLOTHES Trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 390.	1.6	10
100	What's new in atopic eczema? An analysis of systematic reviews published in 2014. Part 1. Epidemiology, risk factors and outcomes. Clinical and Experimental Dermatology, 2016, 41, 843-846.	1.3	10
101	Measuring long-term disease control in patients with atopic dermatitis: A validation study of well-controlled weeks. Journal of Allergy and Clinical Immunology, 2017, 140, 1580-1586.	2.9	10
102	Development of clinical diagnostic criteria for plaque psoriasis in children: an electronic Delphi consensus study with the International Psoriasis Council. British Journal of Dermatology, 2019, 181, 856-857.	1.5	10
103	Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women. BMJ Open, 2021, 11, e053876.	1.9	10
104	Randomized controlled pilot trial with ion exchange water softeners to prevent eczema (SOFTER) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.9	10
105	Vulval erosive lichen planus: a qualitative investigation of U.K. clinician views and principles of management. British Journal of Dermatology, 2013, 169, 226-227.	1.5	9
106	The views of children and young people on the use of silk garments for the treatment of eczema: a nested qualitative study within the <sc>CLOTH</sc> ing for the relief of Eczema Symptoms () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.9	9
107	Identifying the best predictive diagnostic criteria for psoriasis in children (<lt; 18 years): a UK multicentre case-control diagnostic accuracy study (DIPSOC study)*. British Journal of Dermatology, 2022, 186, 341-351.	1.5	9
108	Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg. Trials, 2007, 8, 3.	1.6	8

#	ARTICLE	IF	CITATIONS
109	Studying a disease with no home - lessons in trial recruitment from the PATCH II study. <i>Trials</i> , 2010, 11, 22.	1.6	8
110	Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network. <i>Clinical Investigation</i> , 2011, 1, 943-949.	0.0	8
111	Validation of the global resource of eczema trials (GREAT database). <i>BMC Dermatology</i> , 2015, 15, 4.	2.1	8
112	Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2018, 8, e018649.	1.9	8
113	Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. <i>BMJ Open</i> , 2019, 9, e027168.	1.9	8
114	Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum?. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1216-1220.e2.	1.2	7
115	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020, 185, 139.	1.5	7
116	Supporting families managing childhood eczema: developing and optimising eczema care online using qualitative research. <i>British Journal of General Practice</i> , 2022, 72, e378-e389.	1.4	7
117	What's new in atopic eczema? An analysis of systematic reviews published in 2014. Part 2. Treatment and prevention. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 3-7.	1.3	6
118	What's new in atopic eczema? An analysis of systematic reviews published in 2015. Part 2: prevention and treatment. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 653-658.	1.3	6
119	Different strategies for using topical corticosteroids in people with eczema. <i>The Cochrane Library</i> , 0, , .	2.8	6
120	Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England. <i>BMJ Open</i> , 2020, 10, e035934.	1.9	6
121	An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)*. <i>British Journal of Dermatology</i> , 2021, 184, 840-848.	1.5	6
122	Measurement properties of patient-reported outcome measures for eczema control: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1987-1993.	2.4	6
123	Computer Aided Skin Lesion Diagnosis with Humans in the Loop. <i>Lecture Notes in Computer Science</i> , 2012, , 266-274.	1.3	6
124	Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema. <i>BMJ Open</i> , 2022, 12, e056867.	1.9	6
125	Early recognition and detection of juvenile psoriatic arthritis: a call for a standardized approach to screening. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 153-160.	1.3	5
126	Help for Future Research: Lessons Learned in Trial Design, Recruitment, and Delivery From the "eHELP" Study. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 405-408.	1.9	5

#	ARTICLE	IF	CITATIONS
127	Patients' understanding of cellulitis and their information needs: a mixed-methods study in primary and secondary care. British Journal of General Practice, 2019, 69, e279-e286.	1.4	5
128	Treatment interventions for hand fractures and joint injuries: a scoping review of randomized controlled trials. Journal of Hand Surgery: European Volume, 2020, 45, 111-118.	1.0	5
129	An interview study to determine the experiences of cellulitis diagnosis amongst health care professionals in the UK. BMJ Open, 2020, 10, e034692.	1.9	5
130	A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. Programme Grants for Applied Research, 2016, 4, 1-488.	1.0	5
131	Clinical examination for hyperlinear palms to determine filaggrin genotype: A diagnostic test accuracy study. Clinical and Experimental Allergy, 2021, 51, 1421-1428.	2.9	5
132	Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study. BMJ Open, 2022, 12, e060815.	1.9	5
133	6-sulpho LacNAc dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. Neuropathology and Applied Neurobiology, 2016, 42, 394-398.	3.2	4
134	How do carers and children with eczema choose their emollient?. Clinical and Experimental Dermatology, 2017, 42, 203-203.	1.3	4
135	Feasibility of weekly participant-reported data collection in a pragmatic randomised controlled trial in primary care: experiences from the BATHE trial (Bath Additives for the Treatment of childhood) Tj ETQq1 1 0.78484 rgBT 4Overloc	1.0	4
136	Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. BJGP Open, 2021, 5, BJGPO.2021.0051.	1.8	4
137	The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 240-247.	1.0	4
138	Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability. British Journal of Dermatology, 2022, 187, 548-556.	1.5	4
139	Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study. British Journal of Dermatology, 2022, 187, 919-926.	1.5	4
140	The effect of patients' preference on outcome in the EVERT cryotherapy versus salicylic acid for the treatment of plantar warts (verruca) trial. Journal of Foot and Ankle Research, 2012, 5, 28.	1.9	3
141	The UK Dermatology Clinical Trials Network: how far have we come?. Clinical Investigation, 2014, 4, 209-214.	0.0	3
142	Clearing up misunderstandings around core outcomes for atopic dermatitis. British Journal of Dermatology, 2015, 173, 623-624.	1.5	3
143	Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review. Thorax, 2018, 73, 670-673.	5.6	3
144	Confidence of recurrent cellulitis self-diagnosis among people with lymphoedema: a qualitative interview study. British Journal of General Practice, 2020, 70, e130-e137.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Quality assurance and characterization of narrowband ultraviolet B devices for use at home: lessons from the HILight Vitiligo Trial. British Journal of Dermatology, 2021, 184, 954-955.	1.5	3
146	Do patient characteristics matter when calculating sample size for eczema clinical trials?. Skin Health and Disease, 2021, 1, e42.	1.5	3
147	Could we be doing more to provide an evidence base for rare skin conditions?. British Journal of Dermatology, 2018, 179, 240-241.	1.5	3
148	Atopic Eczema. , 0, , 128-163.		2
149	Dermatology research in primary care: why, what, and how?. British Journal of General Practice, 2011, 61, 89-90.	1.4	2
150	How Often Do Comparative Randomised Controlled Trials in the Field of Eczema Fail to Directly Compare the Treatments Being Tested?. Journal of Clinical Medicine, 2015, 4, 1312-1324.	2.4	2
151	Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial. Trials, 2017, 18, 53.	1.6	2
152	Interviews with paediatric rheumatologists about psoriasis and psoriatic arthritis in children: how can specialties learn from each other?. British Journal of Dermatology, 2017, 177, 316-318.	1.5	2
153	Protocol for a caseâ€control diagnostic accuracy study to develop diagnostic criteria for psoriasis in children (DIPSOC study): a multicentre study recruiting in UK paediatric dermatology clinics. BMJ Open, 2019, 9, e028689.	1.9	2
154	How often are bath emollients prescribed to children with atopic eczema in primary care in England? A crossâ€sectional study. British Journal of Dermatology, 2019, 180, 1252-1253.	1.5	2
155	Scoping the international impact from four independent national dermatology trials. Clinical and Experimental Dermatology, 2021, 46, 657-662.	1.3	2
156	Avoiding hand eczema in healthcare workers. BMJ, The, 2012, 345, e8370-e8370.	6.0	1
157	Author response to van Zuuren etÂal., Penicillin to prevent recurrent cellulitis: a critical appraisal. British Journal of Dermatology, 2014, 171, 1303-1304.	1.5	1
158	<scp>EASI</scp> does it: a comparison of four eczema severity scales. British Journal of Dermatology, 2015, 173, 316-317.	1.5	1
159	Authorsâ€™ reply to Elshimy:. BMJ, The, 2015, 351, h5115.	6.0	1
160	Implementation of blinded outcome assessment in the Effective Verruca Treatments trial (EverT) â€ lessons learned. Journal of Foot and Ankle Research, 2016, 9, 21.	1.9	1
161	Is there an association between study size and reporting of study quality in dermatological clinical trials? A meta-epidemiological review. British Journal of Dermatology, 2017, 176, 1657-1658.	1.5	1
162	The BJD is embracing core outcome set development - why this is good news. British Journal of Dermatology, 2018, 178, 326-327.	1.5	1

#	ARTICLE	IF	CITATIONS
163	What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 376-380.	1.3	1
164	Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. <i>British Journal of General Practice</i> , 2021, 71, e904-e911.	1.4	1
165	Actigraphy for children with eczema. <i>British Journal of Dermatology</i> , 2013, 169, 200-201.	1.5	0
166	Comment on "Management of Vulvovaginal Lichen Planus. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, E23-E24.	1.9	0
167	G258A...Improving the diagnosis of Juvenile Psoriatic Arthritis: How can specialties learn from each other. <i>Archives of Disease in Childhood</i> , 2016, 101, A142-A143.	1.9	0
168	Response from the CLOTHES Trial Team. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e308-e309.	2.4	0
169	Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. <i>BMC Medical Research Methodology</i> , 2021, 21, 22.	3.1	0
170	THU0427...Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities. , 2018, , .		0
171	Celebrating 20 years of the <scp>UK</scp> Dermatology Clinical Trials Network: Part 1 "developing and delivering high quality independent clinical trials. <i>Clinical and Experimental Dermatology</i> , 2022, , .	1.3	0
172	Prescribing and using vitiligo treatments "lessons from a nested Process Evaluation within the <scp>Hl&Light</scp> Vitiligo Randomised Controlled Trial. <i>Clinical and Experimental Dermatology</i> , 2022, , .	1.3	0